[{"id":"27ec7915-3e37-4d12-83f7-0afc1f629fe0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02873819","created_at":"2021-04-27T08:57:21.330Z","updated_at":"2024-07-02T16:36:15.914Z","phase":"Phase 2","brief_title":"Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity","source_id_and_acronym":"NCT02873819","lead_sponsor":"Gliknik Inc.","biomarkers":" MAGEA3","pipe":"","alterations":" ","tags":["MAGEA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • cyclophosphamide • Hiltonol (poly-ICLC) • Leukine (sargramostim) • biropepimut-S (GL-0817) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 03/30/2017","start_date":" 03/30/2017","primary_txt":" Primary completion: 05/17/2021","primary_completion_date":" 05/17/2021","study_txt":" Completion: 05/25/2021","study_completion_date":" 05/25/2021","last_update_posted":"2022-03-08"}]